MeiraGTx Holdings plc Payments of Financing Costs
MeiraGTx Holdings plc (MGTX) reported Payments of Financing Costs of $6.42 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2024-03-15
- MeiraGTx Holdings plc payments of financing costs for the quarter ending 2022-12-31 was $206.00K.
- MeiraGTx Holdings plc payments of financing costs for fiscal 2023 was $6.42M, a 184.36% increase from fiscal 2022.
- MeiraGTx Holdings plc payments of financing costs for fiscal 2022 was $2.26M.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|
| 2023-12-31 | $6.42M 10-K · filed 2024-03-15 | ||
| 2022-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $2.26M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $2.05M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |